PAVmed Inc. Forecasted to Earn FY2022 Earnings of ($1.06) Per Share (NASDAQ:PAVM)

PAVmed Inc. (NASDAQ:PAVMGet Rating) – Equities researchers at Cantor Fitzgerald reduced their FY2022 earnings per share (EPS) estimates for PAVmed in a note issued to investors on Tuesday, November 22nd. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($1.06) per share for the year, down from their previous estimate of ($0.89). The consensus estimate for PAVmed’s current full-year earnings is ($0.89) per share. Cantor Fitzgerald also issued estimates for PAVmed’s FY2023 earnings at ($1.06) EPS.

PAVM has been the topic of several other reports. Ascendiant Capital Markets set a $8.25 target price on PAVmed in a research report on Thursday. Lake Street Capital lowered their target price on PAVmed from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, August 17th.

PAVmed Stock Performance

NASDAQ PAVM opened at $0.76 on Thursday. The company has a market capitalization of $69.14 million, a PE ratio of -0.78 and a beta of 0.77. The business’s fifty day moving average is $1.00 and its 200 day moving average is $1.12. PAVmed has a fifty-two week low of $0.72 and a fifty-two week high of $4.07.

Hedge Funds Weigh In On PAVmed

Several large investors have recently made changes to their positions in PAVM. Pacific Wealth Management bought a new stake in shares of PAVmed in the second quarter worth about $28,000. Guardian Wealth Advisors LLC bought a new stake in shares of PAVmed in the third quarter worth about $30,000. Glassman Wealth Services bought a new stake in shares of PAVmed in the second quarter worth about $33,000. UBS Group AG increased its holdings in shares of PAVmed by 777.9% in the third quarter. UBS Group AG now owns 41,200 shares of the company’s stock worth $35,000 after purchasing an additional 36,507 shares during the last quarter. Finally, Private Advisor Group LLC increased its holdings in shares of PAVmed by 29.9% in the second quarter. Private Advisor Group LLC now owns 41,323 shares of the company’s stock worth $39,000 after purchasing an additional 9,500 shares during the last quarter. 13.40% of the stock is currently owned by hedge funds and other institutional investors.

PAVmed Company Profile

(Get Rating)

PAVmed Inc operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay.

Recommended Stories

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.